Hoth Therapeutics (NASDAQ: HOTH) has revealed its novel asthma and allergy maintenance therapeutic HT-004 “significantly reduces” ovalalbumin (OVA)-induced lung inflammation in mice.
The patient-focused company with headquarters in the US revealed its latest developments came from the sponsored scientific research agreement with North Carolina State University.
HT-004 is still in its early preclinical stage of development, being executed under the guidance of Dr Cruse at North Carolina State University, who is also a member of the Hoth scientific advisory board.
In the testing, mice were treated with HT-004 through inhalation, with results showing a heavily reduced inflammatory cell recruitment in the bronchioles compared to vehicle control and oligonucleotide control OVA-induced mice.
Results from the tests showed the bronchiolar inflation in the HT-004-treated mice was similar to that of the non-OVA simulated mice.
HT-004 potential in human asthma and allergic diseases
The company’s latest developments support the use of HT-004 as a novel inhalation maintenance therapy for asthma and allergic disorders.
Hoth continues to expand its HT-004 development program, aiming to test HT-004’s therapeutic potential in larger animal models, such as cats or dogs, which resemble human asthma and allergic diseases.
The latest results are also a continuation of Dr Cruse’s 2016 publication: Exon skipping of FceRIβ eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy.
Overview of HT-004
Chronic allergic diseases such as eczema and asthma are complex with varying inflammatory responses, which led to Hoth coming up with an alternative therapeutic option in HT-004.
Existing therapeutic approaches aim to suppress the inflammatory response, but are restricted in treating the symptoms and treatment duration is short-lived as a result of unfavourable adverse effects.
HT-004 was developed with the intention to use gene therapy-targeted methods to reduce mast cell responses to immunoglobulin E (IgE)-directed antigens, a key mechanism in the pathophysiology of asthma and other allergic diseases.
Hoth has filed multiple patent applications to protect this IP across the globe.
Clinical-stage biopharmaceutical company Hoth collaborates with scientists, clinicians, and key opinion leaders to uncover therapeutics that have the potential to generate breakthroughs and offer alternative treatment options.
Get the wire before the market opens.
The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.